Country: European Union
Language: English
Source: EMA (European Medicines Agency)
Treprostinil sodium
SciPharm Sàrl
B01AC21
treprostinil
Antithrombotic agents
Hypertension, Pulmonary
Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity.
Revision: 4
Authorised
2020-04-03
31 B. PACKAGE LEAFLET 32 PACKAGE LEAFLET: INFORMATION FOR THE USER TREPULMIX 1 MG/ML SOLUTION FOR INFUSION TREPULMIX 2.5 MG/ML SOLUTION FOR INFUSION TREPULMIX 5 MG/ML SOLUTION FOR INFUSION TREPULMIX 10 MG/ML SOLUTION FOR INFUSION treprostinil READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Trepulmix is and what it is used for 2. What you need to know before you use Trepulmix 3. How to use Trepulmix 4. Possible side effects 5. How to store Trepulmix 6. Contents of the pack and other information 1. WHAT TREPULMIX IS AND WHAT IT IS USED FOR WHAT TREPULMIX IS The active ingredient of Trepulmix is treprostinil. Treprostinil belongs to a group of medicines which work in a similar way to the naturally occurring prostacyclins. Prostacyclins are hormone-like substances which reduce blood pressure by relaxing blood vessels, causing them to widen, which allows the blood to flow more easily. Prostacyclins can also have an influence in preventing blood from clotting. WHAT TREPULMIX IS USED TO TREAT Trepulmix is used for the treatment of adult patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment (severity classified WHO Functional Class (FC) III or IV), to improve exercise capacity and symptoms of the disease. Chronic thromboembolic pulmonary hypertension is a condition where your blood pressure is too high in the blood vessels between the heart and the lungs causing shortness of breath, dizziness, tiredness, fainting, palpitations or abnor Read the complete document
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Trepulmix 1 mg/ml solution for infusion Trepulmix 2.5 mg/ml solution for infusion Trepulmix 5 mg/ml solution for infusion Trepulmix 10 mg/ml solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Trepulmix 1 mg/ml solution for infusion: One ml of solution contains 1 mg treprostinil (as sodium salt). Each 10 ml vial of solution contains 10 mg treprostinil (as sodium salt). _Excipients with known effect _ Each 10 ml vial contains 36.8 mg (1.60 mmol) sodium. Trepulmix 2.5 mg/ml solution for infusion: One ml of solution contains 2.5 mg treprostinil (as sodium salt). Each 10 ml vial of solution contains 25 mg treprostinil (as sodium salt). _Excipients with known effect _ Each 10 ml vial contains 37.3 mg (1.62 mmol) sodium. Trepulmix 5 mg/ml solution for infusion: One ml of solution contains 5 mg treprostinil (as sodium salt). Each 10 ml vial of solution contains 50 mg treprostinil (as sodium salt). _Excipients with known effect _ Each 10 ml vial contains 39.1 mg (1.70 mmol) sodium. Trepulmix 10 mg/ml solution for infusion: One ml of solution contains 10 mg treprostinil (as sodium salt). Each 10 ml vial of solution contains 100 mg treprostinil (as sodium salt). _Excipients with known effect _ Each 10 ml vial contains 37.4 mg (1.63 mmol) sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for infusion. Clear colourless to slightly yellow solution, free from visible particles with a pH of 6.0 – 7.2 and an osmolality between 253 and 284 mOsm/kg. 3 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Trepulmix is indicated for the treatment of adult patients with WHO Functional Class (FC) III or IV and: - inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or - persistent or recurrent CTEPH after surgical treatment to improve exercise capacity. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with Trepulmix should be initiated and monitored only by clinicians experienced in the Read the complete document